Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Abstract: Embodiments of the present technology may include a method of forming an emulsion. The method may include flowing an oil stream and an aqueous stream into a coiled tube to form a mixture of an oil phase and an aqueous phase in the coiled tube. The method may also include flowing the mixture in the coiled tube against gravity and under laminar conditions. A plurality of beads may be disposed within the coiled tube. The method may further include mixing the oil phase and the aqueous phase in the coiled tube until the emulsion is formed.

Abstract: Embodiments of the present technology may include a system for forming an emulsion. The system may include a coiled tube. The coiled tube may have a first end and a second end. The second end may be located at a position higher than the position of the first end. The system may also include a plurality of beads disposed within the coiled tube. The system may further include a first inlet fluidly connected to the coiled tube. The first inlet may be configured to deliver a first fluid to the first end before the second end. In addition, the system may include a second inlet fluidly connected to the coiled tube. The second inlet may be configured to deliver a second fluid to the first end before the second end.

Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Abstract: Embodiments of the present technology may include a system for forming an emulsion. The system may include a coiled tube. The coiled tube may have a first end and a second end. The second end may be located at a position higher than the position of the first end. The system may also include a plurality of beads disposed within the coiled tube. The system may further include a first inlet fluidly connected to the coiled tube. The first inlet may be configured to deliver a first fluid to the first end before the second end. In addition, the system may include a second inlet fluidly connected to the coiled tube. The second inlet may be configured to deliver a second fluid to the first end before the second end.

Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Abstract: Embodiments may include a composition for oral drug delivery. The composition may include a physiologically active substance, a carrier compound, a mucoadhesive compound, and a permeation enhancer. The physiologically active substance may be transported across the stomach. The physiologically active substance may be stable and not degrade in the harsh gastric acid environment. To help protect the physiologically active substance, the physiologically active substance is mixed with the carrier. The carrier may be a liquid insoluble in the gastric acid of the stomach. The physiologically active substance may be soluble in the carrier. The mucoadhesive compound may be used to promote adsorption of the physiologically active substance to the lining of the stomach. The permeation enhancer may facilitate the transport of the physiologically active substance across the wall of the stomach.

Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Abstract: Physiologically active oil-core particles, and a method of making physiologically active oil-core particles that include a hydrophobic core material, a hydrophobic drug dissolved or suspended in the core material, and a layer of amphipathic lipids surrounding the hydrophobic core. An optional continuous phase can be an oil-immiscible solution. In one aspect, the method involves the use of a volatile solvent that is removed after the formation of the suspension. The suspension can be used substantially as created, or the particles formulated as a solid dosage form. In another aspect, the particles are formed substantially simultaneously with the volatilization of a propellant, for example, by spraying through an atomizing actuator. The resulting particles have superior particle size distribution and yield properties.

Abstract: Physiologically active oil-core particles, and a method of making physiologically active oil-core particles that include a hydrophobic core material, a hydrophobic drug dissolved or suspended in the core material, and a layer of amphipathic lipids surrounding the hydrophobic core. An optional continuous phase can be an oil-immiscible solution. In one aspect, the method involves the use of a volatile solvent that is removed after the formation of the suspension. The suspension can be used substantially as created, or the particles formulated as a solid dosage form. In another aspect, the particles are formed substantially simultaneously with the volatilization of a propellant, for example, by spraying through an atomizing actuator. The resulting particles have superior particle size distribution and yield properties.

Abstract: Sustained release of hydrophobic agents may be achieved by incorporation of the agents into liposomes and microspheres. This is achieved by use of a nanosuspension comprising the hydrophobic agent. The nanosuspension may be used as the aqueous solution in the formation of the liposomes and microspheres.